



# Opportunities for U.S. Medical Technologies Companies in Turkish Market

Ebru Olcay

Commercial Specialist – Healthcare Sector

U.S. Commercial Service, Istanbul Turkey

[ebru.olcay@trade.gov](mailto:ebru.olcay@trade.gov)



@DiscoverForums

# Turkey: Its Commercial Potential



# Transformation of Turkish Healthare System

- Quite a laggard system until a decade ago
- **2003 – Introduction of Healthcare Transformation System with support for the World Bank**
  - A very resolute political backing
- **Today;**
  - ↑ population with healthcare insurance
  - ↑ access to healthcare
  - ↑ productivity of healthcare professional
  - ↑ increased patient satisfaction

# Key Players of Turkish Healthcare Market

## Regulator: Ministry of Health

- issues laws and regulations
- registers medical device
- operates public hospitals
- Takes disease prevention measures
- Keeps electronic patient records

## Providers:

- Public Hospitals: 906
- Private Hospitals: 534

## Reimburseurs:

- Social Security Institute
- Private Insurance Companies

## Sellers :

- Manufacturers – directly
- Importers
  - Sub-dealers

# Regulatory Environment

- **Medical device directives aligned to those of EU**
  - Directive 90/385/EEC – implantable medical devices
  - Directive 93/42/EEC – medical devices
  - Directive 98/79/EC – in vitro diagnostic medical devices
- **CE Mark required**
  - FDA, by itself, is not enough

# HealthIT Initiative

## Saglik.Net (health.net)

by Ministry of Health

- **Electronic Health Records**
  - at Primary Care level
- **E-prescription**
- **Telemedicine**
- **E-appointment**

## Medula

by Social Security Institute

- **Drug refills**
- **Payment vehicle**
  - between pharmacies and SGK
- **Drug tracking system**

## Digital Hospital Initiative

by Ministry of Health

- **# of public hospitals with HIS increasing**
- **HIMMS certification**
  - target for public hospitals

# Market Entry – 3R

Representation

- manufacturer's direct office or importer/distributor necessary

Registration

- Product has to be registered with the Ministry of Health Universal Databank

Reimbursement

- Public % of health expenditure: 76%
- Enter SUT list managed by Social Security Institute

# Procurement

- **Public hospitals**
  - Public hospitals grouped into profit centers
  - Each profit center to handle its own procurement
    - by tender
    - important criteria is product's being in SUT list
  - Pricing advantage for local manufacturing – 15%
- **Private hospitals**
  - RFQ
  - Not bound by SUT list unless reimbursed by SGK for the operation

# Market Access

- **U.S. in the group of 'other' countries; no Free Trade Agreement between Turkey and U.S.**
  - sometimes stricter control of documentation at Turkish customs
  - imports tax levied on some products
- **GOT encouraging locally manufactured products**
  - may enforce local assembly or manufacturing for big tenders
- **Sudden changes in reimbursement prices**
- **May soon start charging companies for getting into reimbursement list and staying in the list**

# Key Indicators of Turkish Healthcare Market

- Population: 75 million
- Population growth: 1.2%
- Population over aged 65+: 6.2%
- Life expectancy: 72(M)/77(W)
- Ministry of Health healthcare budget (\$ mil)

year	2010	2011	2012	2013
budget	5,188	6,970	7,442	9,386
growth % YoY		34%	7%	26%

- Health expense per capita (\$)

year	1993	2002	2012
Turkey - health expense per capita \$	124	330	789
OECD average \$	984	1,565	2,386

# Key Indicators of Turkish Healthcare Market

- # of Hospitals and Hospital Beds

	2008	2010	2012	growth % YoY
<b>hospitals</b>	<b>1,308</b>	<b>1,397</b>	<b>1,440</b>	<b>10%</b>
<b>public</b>	<b>908</b>	<b>908</b>	<b>906</b>	<b>0%</b>
<b>private</b>	<b>400</b>	<b>489</b>	<b>534</b>	<b>34%</b>
<b>hospital beds</b>	<b>167,000</b>	<b>184,500</b>	<b>194,000</b>	<b>16%</b>

**45,000** beds will be replaced when 29 health campuses are built by PPP



- # of Patients

(000s)	2008	2010	2012	growth % YoY
<b>inpatient admissions</b>	<b>9,360</b>	<b>11,284</b>	<b>13,604</b>	<b>45%</b>
<b>outpatient visits</b>	<b>276,600</b>	<b>351,800</b>	<b>447,300</b>	<b>62%</b>
<b>surgical procedures</b>	<b>1,370</b>	<b>1,647</b>	<b>1,986</b>	<b>45%</b>



- Growing Medical Tourism

- 42 JCI-accredited hospitals
- 1 million international patients by 2015





<b>Back Musculoskeletal Disorders (Lumbargo, Back Hernia etc)</b>	<b>12.9%</b>
<b>High blood Pressure</b>	<b>12.7%</b>
<b>Rhematoid Arthritis</b>	<b>9.3%</b>
<b>Gastric Ulcer</b>	<b>8.8%</b>
<b>Osteoarthritis</b>	<b>7.5%</b>
<b>Anemia</b>	<b>7.0%</b>
<b>Sinusitis</b>	<b>6.7%</b>
<b>Neck Musculoskeletal Disorders (Neck Pain, Neck Hernia etc)</b>	<b>6.1%</b>
<b>Diabetes</b>	<b>6.0%</b>
<b>Migraine</b>	<b>5.6%</b>
<b>Allergy</b>	<b>5.1%</b>
<b>Asthma</b>	<b>4.8%</b>
<b>Coronary Heart Disease</b>	<b>4.2%</b>
<b>Coronary Obstructive Pulmonary Disease</b>	<b>4.2%</b>
<b>Thyroid</b>	<b>3.3%</b>
<b>Urinary Incontinence</b>	<b>2.2%</b>
<b>Chronic Heart Failure</b>	<b>1.7%</b>
<b>Hepatitis</b>	<b>1.5%</b>
<b>Myocardial Infarction</b>	<b>1.2%</b>
<b>Stroke</b>	<b>1.1%</b>
<b>Duodenal Cancer</b>	<b>1.1%</b>
<b>Liver Dysfunction</b>	<b>0.5%</b>
<b>Cancer (Leukemia, Lymphoma etc)</b>	<b>0.5%</b>

# Key Indicators of Turkish Healthcare Market

- Distribution of Health Problems Diagnosed in 15 and 15+ aged



# Size of Turkish Medical Device Market



# Competition in 2012 by Countries

Country	(\$mil)	
	2012	%
<b>U.S.A.</b>	<b>466</b>	<b>24.2</b>
Germany	311	16.1
China	186	9.7
Malaysia	88	4.6
Japan	84	4.4
Switzerland	82	4.3
Italy	78	4.1
Ireland	78	4.1
UK	75	3.9
France	54	2.8

# Growth Projection



# Potential Areas for U.S. Medical Technologies Companies

- **Consumables:** adhesive medical dressings, safety syringes, cannulae
- Advanced **pre-screening** and **imaging** devices: MRI, Ultrasound, Mamography, CT Scanners
- **Dental Products:** Capital, Instruments and Supplies
- **Orthopedics:** fixation devices, implants
- **Minimally invasive robotic and laporoscopic** surgery equipment
- **Portable aids:** hearing aids, pacemakers
- **Clinical Chemistry** and Laboratory Devices and **Reagents**
  - Biochemistry, immunoassay, blood count tests
  - molecular, genetics, hormone, DNA tests
- **HealthIT systems**

# SWOT Analysis

## Strenghts

- Universal Healthcare System – policial resolve to offer quality healthcare
- Consistent levels of public health expenditure
- Market regulations mostly in line with EU
- 65 medical schools – strong medical education

## Weaknesses

- Challenging reimbursement system - SUT list
- Registration necessary to enter market
- Occasional problems at customs due

## Opportunities

- Dependence on imports for advanced technology
- Upcoming investments:
  - 29 health campuses built under PPP
  - Private hospitals
  - Medical tourism
- Turkish distributors active in Central Asia
- Political resolve behind establishing 'Connected Healthcare Management System'

## Threats

- Global financing availability for PPP projects
- Management of healthcare element of social security budget
- Intensifying global competition
- Cheap and low quality products in the market

Thank you...

[ebru.olcay@trade.gov](mailto:ebru.olcay@trade.gov)